Business
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the "Company" and "Tharimmune") (Nasdaq Capital Market:THAR), a clinical-stage
About this update from Canton Strategic Holdings, Inc.
[{"type":"text","content":"RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the \"Company\" and \"Tharimmune\") (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced the pricing of a registered direct public offering (the \"RD Offering\") with certain purchasers, under the Shelf Registration Statement (as defined below), of up to $1.74 million of the Company's securities (the \"Securities\") consisting of (i) 414,331 shares of Common Stock, par value $0.0001 per share (the \"Common Stock\") and 559,910 pre-funded warrants to acquire shares of Common Stock (the \"RD Pre-Funded Warrants\"), and (ii) 974,241 warrants to acquire shares of Common Stock at the exercise price of $1.66 per share (the \"RD Common Warrant\"), at the price of $1.786 per unit comprised of one share of Common Stock or RD Pre-Funded Warrant and RD Common Warrant purchased, which shall be effected pursuant to the terms of that certain Securities Purchase Agreement (the \"RD SPA).Strategic Investors and Placement DetailsGross proceeds from the offering are expected to be approximately $1.74 million before deducting placement agent fees and estimated offering expenses. Tharimmune intends to use the net proceeds of the offering for working capital and general corporate purposes.President Street Global, LLC is acting as the exclusive placement agent, on a reasonable best-efforts basis for the offering.The closing of the offering is expected to occur on or about July 25, 2025, subject to satisfaction of customary closing conditions.Regulatory DetailsIn relation to the RD Offering, a shelf registration statement on Form S-3 (File No. 333-270684, the \"Shelf Registration Statement\") relating to the securities being offered in the RD Offering was previously filed with the U.S. Securities and Exchange Commission (the \"SEC\") and became effective on March 24, 2023. [In relation to the RD Offering, the shares of common stock and shares underlying the pre-funded warrants are being offered only by means of a prospectus]. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the public offering have been filed with the SEC. A final prospectus supplement and an accompanying prospectus relating to the offering will be filed with the S...